Evidence map›Paper›PMID 42719793›Full record

ArticleFASEB bioAdvances2026

Urotensin II Receptor Deletion Mitigates Kidney Injury and Renal Lipid Remodeling in Mice Fed a Long-Term High-Fat Diet.

Praghalathan Kanthakumar, Adebowale Adebiyi

Abstract read
In one paragraph

Article in FASEB bioAdvances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Praghalathan KanthakumarDepartment of Medical Pharmacology and Physiology University of Missouri Columbia Missouri USA.ORCID https://orcid.org/0000-0002-7610-8945
Adebowale AdebiyiDepartment of Medical Pharmacology and Physiology University of Missouri Columbia Missouri USA.ORCID https://orcid.org/0000-0002-7033-1871

Funding

Urotensin II and renal insufficiency in growth-restricted infants.R01DK127625 · NIDDK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI ADEBIYI, ADEBOWALE · 2020 to 2024
$3.0M
Control of microvascular function by ion channelsR01HL151735 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI ADEBIYI, ADEBOWALE · 2020 to 2023
$2.0M
NHLBI NIH HHS R01 HL151735NIDDK NIH HHS R01 DK127625
6 · The paper itself

Abstract

Urotensin II (UII) signaling through its Gq-coupled receptor (UT) has been implicated in metabolic and vascular dysfunction; however, its contribution to diabetic kidney disease (DKD) and renal lipid remodeling remains incompletely defined. We examined kidney injury and lipidomic alterations in wild-type (WT) and UT knockout (UT KO) mice fed a long-term high-fat diet (HFD). Male WT and UT KO mice were fed HFD (60% kcal fat) or low-fat diet (LFD; 10% kcal fat) for 33 weeks. Despite comparable HFD-induced obesity, hyperglycemia, and hyperinsulinemia, UT deletion significantly attenuated albuminuria, glomerular and tubular fibrosis, histopathologic injury scores, glomerular basement membrane thickening, and podocyte foot process effacement. UT deficiency also reduced systemic and renal markers of endoplasmic reticulum (ER) stress. Untargeted renal lipidomics profiling (1320 lipid species) revealed no genotype-dependent differences under LFD conditions. In contrast, HFD altered 52 lipid species in WT kidneys, prominently affecting phospholipids, glycosphingolipids, ceramides, sphingomyelins, and triglycerides. UT deletion mitigated dysregulation of 41 of these lipid species, indicating that UT signaling promotes maladaptive renal lipid remodeling in DKD. UT expression was confirmed in native and cultured mouse podocytes. In vitro, UII stimulated ER Ca

Indexed as

diabetic kidney diseasehigh‐fat dietpodocytesurotensin II receptor

Identifiers

PMID42719793
PMCPMC13557002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.